|
CN102432585A
|
|
Crystal forms of 1,3,6,7-tetramethoxyxanthone and pharmaceutical composition, preparation method and application thereof
|
|
CN102351835A
|
|
Mangiferin aglycone crystal forms, and composition, preparation method and application thereof
|
|
CN102391336A
|
|
Compound and preparation method and use thereof
|
|
CN102321134A
|
|
Compound, preparation method and application
|
|
CN102351658A
|
|
Method for preparing piceatannol
|
|
CN102228449A
|
|
Gastrodin chronopharmaceutical medicine delivery preparation
|
|
CN102285878B
|
|
Method for preparing 2-halo-4,5-dimethoxy benzoic acid
|
|
CN102240311A
|
|
Application of pseudo-ginseng triol saponin to preparation of medicament for preventing and treating neurodegenerative disease
|
|
CN102452910A
|
|
Preparation method for 3,4,5-trialkoxy phenol
|
|
CN102408415A
|
|
Preparation method of mangiferin
|
|
CN102397281A
|
|
Ginsenoside composition for treating cardiovascular and cerebrovascular diseases
|
|
CN102379886A
|
|
Scutellarin clinical preparation and preparation method thereof
|
|
CN102344475A
|
|
Scutellarin derivative and preparation method and application thereof
|
|
CN102335184A
|
|
Application of 5,6,7,4'-tetrahydroxyflavone and derivatives thereof as JAK tyrosine protein kinase inhibitor
|
|
CN102335164A
|
|
Application of 5,6,7,4'-tetrahydroxy flavone and derivatives thereof in preparation of drugs for preventing and treating hyperuricemia and gout
|
|
CN102260313B
|
|
Amorphous ginsenoside Rb1 and preparation method thereof
|
|
CN102250184A
|
|
Amorphous state ginsenoside Rg1 and preparation method thereof
|
|
CN102247329A
|
|
5,6,7,4'-tetrahydroxyflavone powder injection and preparation method thereof
|
|
CN102247404A
|
|
Pharmaceutical composition for treating lung cancer
|
|
CN101810591A
|
|
Mangiferin dispersible tablets and preparation method thereof
|
